Samsung Biologics increases drug manufacturing contract to KRW 215.9 billion and extends to 2037 ensuring long-term revenue stability

Samsung Biologics amended a drug manufacturing contract with an Asian pharmaceutical company, increasing the contract amount by approximately 49% from KRW 144.6 billion to KRW 215.9 billion.
The contract period was extended by nine years from 2028 to 2037, strengthening long-term revenue visibility, but the counterparty remains undisclosed until 2037 due to business confidentiality, raising governance transparency concerns.
This contract amendment involves no equity issuance or capital changes, eliminating dilution risk for existing shareholders, and the increased minimum guaranteed amount provides stable cash flow prospects.
[AI Summary]The long-term contract expansion and extension for Samsung Biologics enhance revenue visibility without additional capital raising, positively impacting shareholder value, but the undisclosed counterparty introduces slight uncertainty.